Compare WIMI & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIMI | NTRB |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | China | United States |
| Employees | N/A | 3 |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 35.3M |
| IPO Year | 2019 | N/A |
| Metric | WIMI | NTRB |
|---|---|---|
| Price | $1.52 | $3.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 100.7K | 9.2K |
| Earning Date | 04-24-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $2.90 |
| 52 Week High | $5.65 | $9.83 |
| Indicator | WIMI | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 40.06 |
| Support Level | N/A | $2.90 |
| Resistance Level | $1.72 | $3.67 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.57 | 25.81 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.